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ABSTRACT
Objective Investigate the incidence of multiple
sclerosis during 1953–2013 and estimate the prevalence
rate of MS on 1 January 2003 and 2013 in Hordaland
County, Western Norway.
Methods All patients with onset of disease in Hordaland
1953–2013 were identiﬁed in ﬁles from previous studies
until 2003 and from patient records at the departments of
Neurology, Haukeland University Hospital and Haugesund
Hospital during 2003–2013. 1558 patients were assessed
and 1402 of these were included, of whom 1035 were
alive and living in Hordaland at prevalence day 1 January
2013. Annual incidence rates were calculated for
1953–2013.
Results On 1 January 2003, the crude prevalence rate
was 191/100 000 population and on 1 January 2013, the
crude prevalence rate was 211.4 (95% CI 198.3 to 224.2)
per 100 000; 270.9 (95% CI 250.6 to 292.3) for women
and 151.8 (95% CI 136.8 to 167.9) for men. Prevalence
peaked at ages 55–59 years for women and 60–64 years
for men. The annual incidence rate increased from 1.9
(95% CI 1.2 to 2.6) per 100 000 during 1953–1957 to
7.2 (95% CI 6.0 to 8.5) during 1978–1982 and to 8.5
(95% CI 7.3 to 9.7) during 2003–2007, thus indicating a
stabilising incidence over the past 35 years. The female/
male ratio ranged from 1.2:1 to 1.8:1 (p=0.381) during
the period.
Conclusions Stabilising rather than increasing incidence
combined with the stable female/male ratio are indicative
of non-ﬂuctuating environmental factors in a geographical
area otherwise characterised by lack of vitamin D effective
sun exposure. The rising prevalence of MS could result
from improved survival and follow-up methodology.
BACKGROUND
Long-term follow-up studies on prevalence and
incidence of multiple sclerosis (MS) for more than
ﬁve decades are rare and has previously only been
conducted in a 95-year follow-up study in Olmsted
County, Minnesota, USA,1 and a 50-year follow-up
study from Hordaland County, Western Norway.2
Follow-up on the incidence and prevalence of MS
are important to study time trends that can contrib-
ute to analyses of environmental risk factors for
MS and evaluate long-term beneﬁt from disease-
modifying treatment of the disease.
Previously, studies have reported rising preva-
lence of MS in Norway.2–6 We have reported more
than a sevenfold increase of MS prevalence (20 to
150 per 100 000) in Hordaland County during
1953 to 2003 and an increasing incidence until
1978–1982, followed by a high but stable incidence
during the past 30 years.2 7 The cause for the rise
in prevalence is not fully understood and further
investigation of whether the prevalence is still
rising despite a stabilising incidence rate may
increase our understanding of the disease.
We, therefore, present data on a 60-year
follow-up of incidence and prevalence of MS in
Hordaland County, Western Norway. We aimed to
investigate the incidence of MS during 60 years
from 1953 to 2013 and to estimate the prevalence
rate of MS on 1 January 2003 and 2013 in
Hordaland County, Western Norway.
METHODS
Hordaland County is located in Western Norway,
between 59° 300and 61° north, and is characterised
by a long coastal line and inland area with numer-
ous fjords, mountains and valleys. The population
is mainly occupied in industry, including oil and gas
production, commerce and service, ﬁsheries and
agriculture. The population in Hordaland County
increased from 317 384 on 1 January 1953 to
441 660 on 1 January 2003 and to 490 570 on
1 January 2013. Nearly half of the population lives
in the administrative centre in the city of Bergen
and half of the population lives in small villages
and rural areas. The migration rate ranged between
3.6% and 4.7% during 1973–2007, and between
8.7% and 9.7% during 2008–2012. During 2001–
2009, the population grew by 1% annually, mainly
due to immigration.
Data collection and study population
Data ﬁles from previous epidemiological studies
conducted during 1953–2003 were available2 8–11
and patients’ records were reassessed according to
mortality and place of residence on the prevalence
day, 1 January 2013. Additional patients diagnosed
after 2003 were identiﬁed from the patient records
at the Department of Neurology at Haukeland
University Hospital, Bergen. The department was
established in 1953 and is responsible for the
neurological health service to residents in central
and northern regions of Hordaland County. Owing
to administrative changes, patients living in the
southern regions of Hordaland County have been
referred to Haugesund Hospital during the last
decade. Thus, a total of 37 patients were identiﬁed
from patient records at the department of
Neurology at Haugesund Hospital. All patients
with MS in Hordaland County are referred to
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these two neurological departments for diagnostic cerebrospinal
ﬂuid (CSF) analysis and disease-modifying treatment. Thus all
patients diagnosed with MS in Hordaland County are therefore
most likely included in the sample. All patients were referred
from general practice and private neurological practices to the
hospital for diagnostic evaluation, including MRI and CSF ana-
lysis. Statistics Norway (http://www.ssb.no) and the National
Population Registry provided data on the patient’s place of resi-
dence at the time of disease onset and on prevalence day, as well
as the total population in the county.
All patient records were reviewed and scrutinised for data on
gender, age, place and year of birth, course of disease at onset,
year of disease onset and year of diagnosis. Onset of disease was
deﬁned as the year of the ﬁrst symptom(s). Time of diagnosis
was deﬁned as the year a neurologist made the diagnosis. The
clinical course at onset was classiﬁed as relapsing–remitting or
primary–progressive MS. Onset from 1953 were classiﬁed
according to the diagnostic criteria of Poser12 and onset from
2003 onwards were classiﬁed according to the revised (2010)
diagnostic criteria of McDonald.13 Patients initially diagnosed
with MS who later received another diagnosis were excluded
from the study. Patients with onset of MS during 1953–2013
while living in the county of Hordaland, who had moved out of
the county prior to the prevalence day were included in the inci-
dence analyses, but excluded from the prevalence analyses.
Patients still alive and living in the county with MS onset prior
to 1953 were excluded from the incidence analyses, but
included in the prevalence analyses. Similarly, all patients with
onset outside Hordaland County and who later immigrated
were excluded from the incidence analyses, but included in the
prevalence rates.
When calculating the prevalence in 2013, patients who had
emigrated or died between 2003 and 2013 were excluded.
The study was approved by the Regional Committee for
Medical and Health Research Ethics in Western Norway.
Prevalence and incidence
The prevalence rate was deﬁned as the total number of patients
with MS with deﬁnite13 or probable MS12 per 100 000 inhabi-
tants living in Hordaland County on 1 January 2013. The crude
annual incidence rate of MS was deﬁned as the number of
patients with onset of disease per 100 000 inhabitants per year.
Statistical analysis
Calculation of CI for prevalence and incidence as well as the
test for trend in incidence were based on the assumption that
the number of cases each year follows a Poisson distribution.
Given the heavily skewed distribution, the Mann-Whitney test
was used to test for difference in time from onset of disease to
diagnosis. In the other bivariate comparison, the Student t test
was used. One way analysis of variance was used to test differ-
ence in age at onset between different diagnostic classiﬁcations.
The statistical software packages IBM SPSS Statistics V.21 and
StatXact 9 (Cytel Software, Cambridge, Massachusetts, USA)
were used to perform the analysis.
RESULTS
A total of 1558 patients had received a diagnosis of MS during
1953–2013 at the departments of Neurology at Haukeland
University Hospital and Haugesund Hospital. On prevalence
day, 1 January 2013, a total of 393 were deceased and 130 were
not resident in Hordaland County, leaving 1035 still alive and
living in the county. A total of 1402 patients had onset of MS
when living in Hordaland County.
A total of 493 (46.7%) were classiﬁed as deﬁnite MS and 112
(10.8%) were classiﬁed as probable MS according to Poser cri-
teria, and 430 (41.5%) were classiﬁed as deﬁnite MS according
to McDonald criteria (table 1).
Relapsing–remitting course at disease onset was detected in
950 (91.8%) and primary progressive course was found in 85
(8.2%). The mean age at onset was 31.8 years; 31.7 years for
patients with deﬁnite MS, 33 years for patients with probable
MS according to Poser criteria12 and 31.5 years for patients
diagnosed with MS according to McDonald’s criteria13
(p=0.97). The female proportion was 63.8% and the F/M ratio
was 1.8:1 on prevalence day, 1 January 2013.
The average time interval between onset and diagnosis of MS
declined from median 21 (range 9–40) years during 1953–1957
to 1.3 (range 0–9) years during 2003–2007, (p<0.0001) in the
prevalence cohort (ﬁgure 1).
Since the last follow-up,2 a total of 135 patients were
included with onset prior to 2003 and diagnosed with MS
during 2003–2013. By including these patients and patients
from Haugesund Hospital the 2003-prevalence increased from
1502 to 191/100 000 (N=842). A total of 142 patients immi-
grated to Hordaland during 2003–2013 of whom 112 had
disease onset prior to 2003. A total of 179 patients emigrated,
of whom 49 were deceased by 2013 and 140 had disease onset
prior to 2003.
Prevalence
On 1 January 2013, the crude prevalence rate was 211.4 (95%
CI 198.3 to 224.2) per 100 000 inhabitants, 270.9 (95% CI
250.6 to 292.3) for women and 151.8 (95% CI 136.8 to
167.9) for men. The peak age-speciﬁc prevalence appeared
highest in women aged 55–59 years and in men aged 60–
64 years (ﬁgure 2).
Compared with the 2003 follow-up,2 the prevalence is higher
in older ages, age 60–64, in 2013 (ﬁgure 3). Since 1957, the
prevalence in Hordaland County increased from about 207 to
60 in 19839 and to 211/100 000 in 2013. The 2003 prevalence
increased from 150 reported in the previous follow-up2 to 191
in the present study.
Incidence
The annual incidence rate increased signiﬁcantly during the
study period analysed by 5-year intervals (p<0.0001) from
Table 1 Demographic and clinical data for patients with multiple
sclerosis on prevalence day, 1 January 2013
n
Per
cent
Mean age at
onset (years)
p
Value
Diagnostic classification
Poser
Definite MS 493 47.6 31.7 0.97
Probable MS 112 10.8 33.0
McDonald 430 41.5 31.5
Course of disease at onset
Remitting–relapsing MS 950 91.8 30.7 0.065
Primary–progressive MS 85 8.2 43.8
Gender
Women 660 63.8 33.4 0.35
Men 375 36.2 34.3
Total 1035 31.8
MS, multiple sclerosis.
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1.9/100 000 inhabitants during 1953–1957 to 8.2 during 2003–
2007, followed by a decline to 5.2/100 000 during 2007–2013.
The incidence increased during the ﬁrst 25 years (p=0.00019),
until stabilising at a high level, ranging from 7.2 to 8.5 since
1978 (p=0.20; ﬁgure 4). The incidence increased in both
genders and the overall sex ratio at onset did not signiﬁcantly
change during the study period, ranging from 1.2:1 to 1.8:1
(p=0.381).
DISCUSSION
We provide a 60-year follow-up of incidence and prevalence of
MS in Hordaland County, Western Norway, showing an increas-
ing prevalence over the total period, but a stabilising incidence
since 1978.
The prevalence increased 10-fold from 20/100 000 in 1963
to 211 (95% CI 198.3 to 224.2) per 100 000 in 2013. The
prevalence rate of 211/100 000 inhabitants was higher than a
recent prevalence report of 186/100 000 in Western Norway.3
These diverging results are most likely a result of the limitation
of using data from the National Patients Registry included in
this recent nationwide study.3 Previous Norwegian studies using
hospital records (as in our study) have reported MS prevalence
rates of 170/100 000 in the south-eastern county of Oslo,5 180/
100 000 in the southern county of Vest-Agder6 and 185.6/
100 000 in the eastern county of Oppland.14 The prevalence
rate in Hordaland was, thus, similar to the latest report from
the UK,15 but higher than reported in Denmark,16 Sweden17
and South East Wales,24 and lower than reports from Orkney,
Shetland and Aberdeen City,36 all geographical areas close to
Hordaland County.
Comparing MS prevalence in Hordaland County on preva-
lence day 1 January 2003 calculated in 20032 at 150/100 000
with the present study including follow-up until 2013 giving
191/100 000, highlights the importance of the sample collection
termination day, in order to calculate the valid prevalence.
Thus, the follow-up identiﬁed undiagnosed patients who had
symptom onset prior to 1 January 2003 and illustrates that the
prevalence is rising and most interestingly, that the date for
study termination has a major impact on prevalence. The rise in
prevalence is a consequence of the underestimated prevalence
reported previously2 due to the time delay between onset and
diagnosis. However, the time delay between onset and diagnosis
is decreasing and consequently, the methodological issue of
underestimated prevalence will probably be reduced in future
studies.
The incidence of MS in Hordaland County has in previous
studies increased from 0.2/100 000 in 1935,10 to 0.67/100 000
in 195111 and to 4.7/100 000 in 1978–1982.9 However, in the
present long-term follow-up study, we also identiﬁed patients
with disease onset years prior and thus higher incidence rates of
1.8/100 000 during 1953–1957, 6.9/100 000 during 1978–
1982 followed by a stable high level of approximately 7–8/
100 000 during later years. Thus, this tendency towards increase
in incidence rates and prevalence rates of MS, presented in the
repeated studies we provide in this paper, demonstrates the
necessity of repeated surveillance to study valid time trends of
MS incidence rates.23
Figure 1 Time delay from onset of
disease until diagnosis of multiple
sclerosis, in 5-year periods 1953–2013.
Figure 2 Age-speciﬁc prevalence rates of multiple sclerosis (MS) by
gender on 1 January 2013.
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The incidence of 8.5/100 000 inhabitants during 2003–2007
was similar to reports from previous reports on MS frequency
in the southern6 and eastern14 parts of Norway, conﬁrming
Norway as a high risk area of MS without any evidence of a lati-
tude gradient.3
We showed relatively stable incidence rates during the past
three decades. However, since we reported the year-of-onset
incidence, we observed a drop in rate probably due to delayed
diagnosed cases for the latest 5-year period. The stable inci-
dence rate was consistent with reports from Olmstead County,
Minnesota, USA,1 and Canada,18 but was in contrast to a down-
ward incidence trend in the Orkney Islands,21 the Faroe
Islands19 and in Gothenburg,22 and the increased incidence
trends in Denmark,23 South East-Wales,24 Northeast Ireland25
and another Canadian population.26
The rise in prevalence of MS could partly be explained by the
historical large increase in incidence of the disease until 1978–
1982. The early increase in prevalence might be explained by
the increase in incidence the ﬁrst 3–4 decades. Also, owing to
the onset of disease approach to incidence and prevalence esti-
mations, and the time delay between onset and diagnosis, the
prevalence has a delay up to about mean 7–9 years until the
1990’s and hence, increase in incidence is followed by a parallel
increase in prevalence after almost a decade. Because of the
retrospective year of onset approach to incidence, the preva-
lence is catching up later. However, the continued recent
increase in prevalence was not associated with a parallel increase
in incidence. Thus some of the increase in prevalence in recent
years may be explained by improved diagnostics especially with
the introduction of MRI in the 1990s and the ability to identify
younger patients and more benign disease living longer with the
disease. The diagnostic criteria which has evolved from the
early clinically based criteria12 to MRI-grounded criteria,27
recently revised,13 have improved case ascertainment through-
out the study period. Systematic use of the revised diagnostic
criteria of McDonald with frequent use of repeated MRIs may
Figure 3 Age-speciﬁc prevalence
rates of multiple sclerosis (MS) in 2003
and 2013.
Figure 4 Total crude annual incidence rates per 100 000 populations of multiple sclerosis (MS) with onset 1953–2013 in 5-year periods by
gender.
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lead to an increased diagnosis of patients with vague symptoms
due to a benign disease. However, the diagnosing of more
benign cases had probably a limited impact on prevalence,
leaving increased survival as the most likely explanation to our
ﬁndings. Improved survival in MS, possible due to more fre-
quent use of advanced disease-modifying therapies,28 was prob-
ably the most important factor related to the observed increase
in prevalence. The importance of improved survival on the
observed increase in prevalence was also supported by the shift
towards an older age distribution of the present 2013 preva-
lence cohort compared with the prevalence reported in the
2003 study.2 A change in age distribution has also previously
been reported from Canada and the UK.15 18
Given the stable incidence rate, the higher ages in the cohort
probably relate to improved survival either due to disease-
modifying therapies or attributed to a general increase in life
expectancy during the last decades. To determine the impact of
treatment on survival, standardised mortality ratio calculations
comparing MS to the general population in Norway are
needed.29
In contrast to several reports of increasing female to male
ratios in MS24 30 31 the overall rate has been stable in
Hordaland County throughout the past six decades. Our
follow-up data showed a stable sex-ratio throughout the period
and does not indicate gender-speciﬁc environmental risk factors
which affect women more than men.
Explaining the stable incidence rates by changes in environ-
mental risk factors for MS seems challenging. Epstein-Barr
virus20 infections are stable, but cigarette smoking32 has declined
during the last decades (https://www.ssb.no/statistikkbanken/
selectvarval/saveselections.asp) and may have reduced the risk of
MS. However, both consumption of dietary salt intake33 through
processed food and use of sun-protection products,34 which may
lead to reduced serum levels of vitamin D35 has increased in the
past three decades. These may be two other factors associated
with increased risk of MS.
Improved case ascertainment during the past six decades can
probably explain some of the increased prevalence found in the
present study. This was indicated by the steady decline in time
delay between onset and diagnosis of MS. Revised diagnostic
criteria,13 focusing on active use of MRI to deﬁne disseminated
disease in time and space, combined with improved disease-
modifying treatments has increased the diagnostic awareness
among physicians and patients, and have therefore, important
impact on this time-delay.
Our study provides comprehensive data on MS prevalence
and incidence during 60 years and conﬁrms Norway as a high
risk area for MS. The steady increase in MS incidence from the
1950s followed by a stable high incidence during the past three
decades, calls for further studies focusing on environmental
factors to explain this pattern. The tendency to identify more
MS cases at follow-up, demonstrated in this study, indicates that
previous studies with data collection close to the prevalence day
might have underestimated the prevalence of MS. Thus future
studies on prevalence of MS should explore the occurrence of
disease with a prolonged follow-up of several years after preva-
lence day in order to estimate the true prevalence of disease.
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